Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease

Hideo Gobara, Atsuhiro Nakatsuka, Kanichiro Shimizu, Takashi Yamanaka, Yusuke Matsui, Toshihiro Iguchi, Takao Hiraki, Koichiro Yamakado

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.

Original languageEnglish
JournalJapanese Journal of Radiology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Cryosurgery
Chronic Renal Insufficiency
Renal Cell Carcinoma
Glomerular Filtration Rate
Renal Dialysis
Neoplasms
Multicenter Studies
Therapeutics
Retrospective Studies
Kidney
Safety

Keywords

  • Chronic kidney disease
  • Cryoablation
  • Kidney
  • Renal cell carcinoma
  • Stage 4

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease. / Gobara, Hideo; Nakatsuka, Atsuhiro; Shimizu, Kanichiro; Yamanaka, Takashi; Matsui, Yusuke; Iguchi, Toshihiro; Hiraki, Takao; Yamakado, Koichiro.

In: Japanese Journal of Radiology, 01.01.2019.

Research output: Contribution to journalArticle

@article{6a9b2e37e8f64d67bb359d55c5fd1305,
title = "Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease",
abstract = "Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1{\%}; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.",
keywords = "Chronic kidney disease, Cryoablation, Kidney, Renal cell carcinoma, Stage 4",
author = "Hideo Gobara and Atsuhiro Nakatsuka and Kanichiro Shimizu and Takashi Yamanaka and Yusuke Matsui and Toshihiro Iguchi and Takao Hiraki and Koichiro Yamakado",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11604-019-00821-7",
language = "English",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease

AU - Gobara, Hideo

AU - Nakatsuka, Atsuhiro

AU - Shimizu, Kanichiro

AU - Yamanaka, Takashi

AU - Matsui, Yusuke

AU - Iguchi, Toshihiro

AU - Hiraki, Takao

AU - Yamakado, Koichiro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.

AB - Purpose: To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD). Materials and methods: This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 , in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016. Results: Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m 2 . The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up. Conclusion: Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.

KW - Chronic kidney disease

KW - Cryoablation

KW - Kidney

KW - Renal cell carcinoma

KW - Stage 4

UR - http://www.scopus.com/inward/record.url?scp=85064270385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064270385&partnerID=8YFLogxK

U2 - 10.1007/s11604-019-00821-7

DO - 10.1007/s11604-019-00821-7

M3 - Article

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

ER -